SCHEMBL1980276

SCHEMBL1980276

CCc1ccccc1Oc1ccc([N+](=O)[O-])cn1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSPB1 P04792 2/20 0.56
MAPT P10636 6/20 0.48
L3MBTL1 Q9Y468 4/20 0.48
ALDH1A1 P00352 4/20 0.48
KDM4E B2RXH2 1/20 0.48
GAA P10253 1/20 0.48
NPSR1 Q6W5P4 1/20 0.47
MEN1 O00255 5/20 0.46
KMT2A Q03164 5/20 0.46
PABPC1 P11940 1/20 0.46
POLB P06746 1/20 0.46
PKM P14618 1/20 0.46
SMN1; SMN2 Q16637 4/20 0.45
LMNA P02545 4/20 0.45
HTT P42858 3/20 0.45
GABRA5 P31644 1/20 0.45
SLC6A2 P23975 2/20 0.43
SLC6A4 P31645 2/20 0.43
SLC6A3 Q01959 2/20 0.43
HPGD P15428 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7810838 0.85 HSPB1 (0.53) HSPB1MAPTL3MBTL1ALDH1A1KDM4E
SCHEMBL17571121 0.83 HSPB1 (0.59) HSPB1MAPTL3MBTL1ALDH1A1KDM4E
SCHEMBL25200788 0.83 HSPB1 (0.59) HSPB1MAPTL3MBTL1ALDH1A1KDM4E
SCHEMBL25184221 0.80 KMT2A (0.60) HSPB1MAPTL3MBTL1ALDH1A1GAA
SCHEMBL16792542 0.80 HSPB1 (0.75) HSPB1MAPTL3MBTL1ALDH1A1KDM4E
SCHEMBL3158871 0.80 HSPB1 (0.55) HSPB1MAPTL3MBTL1ALDH1A1KDM4E
SCHEMBL11133456 0.79 HSPB1 (0.58) HSPB1MAPTL3MBTL1ALDH1A1KDM4E
SCHEMBL25500681 0.79 MAPT (0.61) HSPB1MAPTL3MBTL1ALDH1A1KDM4E
SCHEMBL6179891 0.78 HSPB1 (0.54) HSPB1MAPTL3MBTL1ALDH1A1KDM4E
SCHEMBL27449389 0.78 HSPB1 (0.70) HSPB1MAPTL3MBTL1ALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200163964-A1 IMIDAZOLIDINEDIONE DERIVATIVES AUTIFONY THERAPEUTICS LIMITED (GB) 2020-05-28 US disclosed
US-20200163964-A1 IMIDAZOLIDINEDIONE DERIVATIVES AUTIFONY THERAPEUTICS LIMITED (GB) 2020-05-28 US disclosed
US-10632118-B2 Imidazolidinedione derivatives AUTIFONY THERAPEUTICS LIMITED (GB) 2020-04-28 US disclosed
US-20180338974-A1 IMIDAZOLIDINEDIONE DERIVATIVES AUTIFONY THERAPEUTICS LIMITED (GB) 2018-11-29 US disclosed
US-10058551-B2 Imidazolidinedione derivatives AUTIFONY THERAPEUTICS LIMITED (GB) 2018-08-28 US disclosed
US-20180021336-A1 IMIDAZOLIDINEDIONE DERIVATIVES AUTIFONY THERAPEUTICS LIMITED (GB) 2018-01-25 US disclosed
US-20180021336-A1 IMIDAZOLIDINEDIONE DERIVATIVES AUTIFONY THERAPEUTICS LIMITED (GB) 2018-01-25 US disclosed
US-20180021336-A1 IMIDAZOLIDINEDIONE DERIVATIVES AUTIFONY THERAPEUTICS LIMITED (GB) 2018-01-25 US disclosed
US-9849131-B2 Imidazolidinedione derivatives AUTIFONY THERAPEUTICS LIMITED (GB) 2017-12-26 US disclosed
US-9849131-B2 Imidazolidinedione derivatives AUTIFONY THERAPEUTICS LIMITED (GB) 2017-12-26 US disclosed
US-9216967-B2 Imidazolidinedione derivatives AUTIFONY THERAPEUTICS LIMITED (GB) 2015-12-22 US disclosed
US-8722695-B2 Imidazolidinedione derivatives AUTIFONY THERAPEUTICS LIMITED (GB) 2014-05-13 US disclosed
US-8722695-B2 Imidazolidinedione derivatives AUTIFONY THERAPEUTICS LIMITED (GB) 2014-05-13 US disclosed
US-8722695-B2 Imidazolidinedione derivatives AUTIFONY THERAPEUTICS LIMITED (GB) 2014-05-13 US disclosed
US-20120289526-A1 IMIDAZOLIDINEDIONE DERIVATIVES AUTIFONY THERAPEUTICS LIMITED (GB) 2012-11-15 US disclosed
US-20120289526-A1 IMIDAZOLIDINEDIONE DERIVATIVES AUTIFONY THERAPEUTICS LIMITED (GB) 2012-11-15 US disclosed
US-20120289526-A1 IMIDAZOLIDINEDIONE DERIVATIVES AUTIFONY THERAPEUTICS LIMITED (GB) 2012-11-15 US disclosed
EP-2509961-A1 IMIDAZOLIDINEDIONE DERIVATIVES Autifony Therapeutics Limited (GB) 2012-10-17 EP disclosed
WO-2011069951-A1 IMIDAZOLIDINEDIONE DERIVATIVES GLAXO GROUP LIMITED (GB) 2011-06-16 WO disclosed
WO-2011069951-A1 IMIDAZOLIDINEDIONE DERIVATIVES GLAXO GROUP LIMITED (GB) 2011-06-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180338974-A1 IMIDAZOLIDINEDIONE DERIVATIVES KCND3, KCNK3, KCNA3 HSPB1 4360/4885MAPT 3762/4885L3MBTL1 4332/4885
US-20180021336-A1 IMIDAZOLIDINEDIONE DERIVATIVES KCND3, KCNK3, KCNA3 HSPB1 4360/4885MAPT 3762/4885L3MBTL1 4332/4885
US-10632118-B2 Imidazolidinedione derivatives KCND3, KCNK3, KCNA3 HSPB1 4360/4885MAPT 3762/4885L3MBTL1 4332/4885
US-10058551-B2 Imidazolidinedione derivatives KCND3, KCNK3, KCNA3 HSPB1 4360/4885MAPT 3762/4885L3MBTL1 4332/4885
US-20200163964-A1 IMIDAZOLIDINEDIONE DERIVATIVES KCND3, KCNK3, KCNA3 HSPB1 4360/4885MAPT 3762/4885L3MBTL1 4332/4885
US-20120289526-A1 IMIDAZOLIDINEDIONE DERIVATIVES KCND3, KCNK3, KCNA3 HSPB1 4599/4885MAPT 3789/4885L3MBTL1 4300/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.